Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
When they were introduced 12 years ago, the two small, easy-to-use devices helped Steve Jobs and Apple revolutionise how music was sold.
But, as the trend continues towards streaming services, Apple has decided to ditch the portable MP3 players.
So, today we’re asking you: Did you ever own an iPod nano or shuffle?
Poll Results:
Yes (6435)
No, but had MP3 players (1358)
No, never bothered with such devices (1102)
No, my walkman still works fine (192)
Advertisement
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
How a pharmaceutical company think can justify those prices is crazy. I appreciate millions goes into research and development for these drugs but putting a price tag of €150,000 per patient per year? This is nothing short of extortion! Give people living with CF a chance of a better life, they’ve struggled enough as it is.
@ shane its called greed. The World is just Greed today. And this is nothing to what can happen in the next 20 years maybe sooner. No P R S I everyone will have to have private medical ins. No dole ( that could be a good thing for those who never worked in their life or for a few years) we are becoming like America and the Rich get richer and poor get poorer.
Again. Why are we not raising this issue I.e. the fact that as a small country, we are being scrxxxd by pharmaceutical companies, with the EU and benefiting from economies of scale associated, we could call it a common health policy or are common EU actions confined to agriculture and fisheries?
The public should realise this is not just a CF orkambi problem. We are all faced with the reality of this problem if we become sick and depend on compassionate access programs or drug trials for our treatment, a company will not supply drugs indefinitely if they do not see themselves getting a market share at some stage in future. Yes the drugs work for a percentage of patients and when it does it’s an amazing chance at a good quality of life for the patients, but it will not work for everyone that is reality how do you balance the cost of a drug against its effectiveness that’s where NCPE come in to play, we are lucky some countries don’t even have a HTA system in place, and their governments don’t provide any drugs for often terminal conditions, our system isn’t perfect but neither are any of them I have seen throughout Europe. This year in a media storm a new drug was refused for malignant melanoma patients and the minister pleaded for extension of the compassionate program from BMS that extension ended since august no newly diagnosed patients have received it since then, in November a second drug approval of a combination therapy for melanoma patients was refused also because of the price submitted this is by far the best treatment to date for advanced melanoma , this is not a CF problem this is a international drug pricing problem that effects many diseases and as an advanced stage Melanoma patient I am deeply upset it’s being portrayed as one drug on disease problem
Martin no price should be put on a life: but we do. The health budget is 16 billion per year or thereabouts. That’s the price we put on the health of the nation. If Orkambi was a million per year per patient would you still pay it? Of course not. What about a hundred euro per year? In that case we wouldn’t be having the discussion. So clearly somewhere in the middle there is a cost point where we say the benefit is not worth the cost. Sociologists have worked out this as willingness to pay thresholds. In the U.K. It is something like 20,000 pounds ie the average person thinks that is a reasonable amount to pay for one quality of life year gained. Yes it is populist to say you can’t put a price on a life but we must and we do as resources are finite. It is a sad reality.
Martin, In theory I would agree with you but when our health service has a limited budget for drugs what else would you suggest? Bearing in mind CF is one of a spectrum of diseases which the Irish population need drugs/treatments for. How would you suggest the HSE priorities which drugs and purchases and for what diseases?
@Martin Ryan So Martin if a loved one was in a vegetative state but could be kept alive indefinitely at a cost of €50,000 a year or removed from life support at no cost apart from their death, which would you go for?
I presume you’d have to think about it and discuss it with your family and weigh up the cost/benefit aspects?
You would effectively be putting a price on life.
Ah a nice rehash of the article from yesterday, i will say again the patients themselves are the ones putting themselves into the position of being a bargaining chip as they want it paid at all cost.
How the hell can a functioning health service work if we have every niche group pushing for expensive drugs to be paid for. There really has to be a cost benefit analysis because we save a small group here and another and another and quite soon service overall get worse than they already are.
There is a cost benefit analysis they use Qlays quality life adjusted years it is how they assess if the drugs provide extra years that are lived with some quality of life for a patient this is what NCPE was set up to assess. They have deemed Orkambi and also the drugs I need as too expensive and as a patient who has done a lot of study on this even though I need the drugs I agree. We cannot sustain this kind of expenditure on drugs what about next year when the next drug comes along do we shout and demand that one too at whatever price pharma decides to put on it? The whole system is broken but if we are going to allow these companies to set up base here in our country to manufacture we should at least reap the benefits of what they produce instead of the drugs being exported to countries that are willing to pay whatever is asked we are happy to accommodate them for employment An tax returns even if those taxes are very much in their favour we need more in return we all contribute to collections for research into new treatments why don’t we see the benefit why do the shareholders and CEO gain while we suffer the system is broken from the bottom to the top so you can’t blame patients for becoming desperate and shouting because they feel no one is listening and time is running out
They should count themselves lucky that they even have access to drugs. There’s no cure for my disease and realistically there never will be. Gambling forced me to steal from my friends and family as well as star in gay adult movies and cheat on my partner with an underage girl (she showed me a picture of a Jaguar she said she drove so I presumed she wasn’t 15). I’m the real victim here.
There is a relatively small number of Irish people who need this drug to improve and prolong their lives.
Despite the high cost involved, in the context of the small number of people needing it, it would amount to a tiny minute fraction of the HSE budget. We are not talking about tens of users
Other European countries are buying the drug for their CF citizens.
It’s a cop out by the government/HSE to refuse to buy.
Martin, there is around 1100 CF sufferers in Ireland, should all of them access this drug that accumulates to €176 million per year. Put into context Beaumont Hospital cost around €230 million a year to run. It’s not scare mongering to say smaller regional hospitals could be closed to pay for this one drug. There is finite funds, we need to manage them. It might sound inhumane but it is not financially viable to provide this drug. While it may benefit the 1100 patients, far more would suffer in the long run due to other service cuts
Medicines and advertising regulators examine Ozempic maker's Irish ads
8 hrs ago
6.0k
Kashmir
India and Pakistan trade blame as ceasefire violated within hours of agreement being reached
11 mins ago
0
0
Cannabis
Former Ryanair pilot charged with possession of €10m worth of drugs and refused bail
Updated
14 hrs ago
47.6k
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 187 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 126 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 165 partners can use this purpose
Use limited data to select advertising 129 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 91 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 92 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 44 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 41 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 150 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 69 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 88 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 95 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 40 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 56 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 29 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 107 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 111 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 79 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 60 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 100 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 83 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say